Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STC 15

Next Previous
Drug Profile

STC 15

Alternative Names: STC-15

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evotec SE; Storm Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Amines; Antineoplastics; Cyclobutanes; Indoles; Ketones; Pyridines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action METTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Solid tumours
  • No development reported Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 02 Jun 2026 Efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 24 Apr 2026 STC 15 is still in phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05584111)
  • 16 Apr 2026 Storm Therapeutics plans to submit the regulatory application for the accelerated approval of STC 15

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top